G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 25.4 PLN Market Closed
Market Cap: 33.5m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genomed SA
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Cash from Investing Activities
-zł203.9k
CAGR 3-Years
41%
CAGR 5-Years
32%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Cash from Investing Activities
-zł31.3m
CAGR 3-Years
-21%
CAGR 5-Years
-23%
CAGR 10-Years
2%
R
Read Gene SA
WSE:RDG
Cash from Investing Activities
-zł4.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-83%
B
Bioton SA
WSE:BIO
Cash from Investing Activities
-zł24.6m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Cash from Investing Activities
-zł24.4m
CAGR 3-Years
-734%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Cash from Investing Activities
-zł75.1m
CAGR 3-Years
-149%
CAGR 5-Years
-107%
CAGR 10-Years
-41%
No Stocks Found

Genomed SA
Glance View

Market Cap
33.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Fairly Valued
Intrinsic Value
Price
G

See Also

What is Genomed SA's Cash from Investing Activities?
Cash from Investing Activities
-203.9k PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Cash from Investing Activities amounts to -203.9k PLN.

What is Genomed SA's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
32%

Over the last year, the Cash from Investing Activities growth was 17%. The average annual Cash from Investing Activities growth rates for Genomed SA have been 41% over the past three years , 32% over the past five years .

Back to Top